君实生物跌1.3% 连亏9年3季2020年上市2募资共86亿

Core Viewpoint - Junshi Biosciences (688180.SH) is currently trading at 38.69 yuan, reflecting a decline of 1.30% and is in a state of share price decline since its IPO [1] Fundraising and Financial Performance - Junshi Biosciences was listed on the Shanghai Stock Exchange's STAR Market on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share, raising a total of 4.836 billion yuan, netting 4.497 billion yuan after expenses [2][3] - The company planned to raise 2.7 billion yuan for innovative drug research, industrialization projects, loan repayment, and working capital [2] - The total fundraising from two rounds amounts to 8.612 billion yuan [4] - In the years from 2016 to 2024, the net profit attributable to shareholders has shown consistent losses, with figures of -1.35 billion, -3.17 billion, -7.23 billion, -7.47 billion, -16.69 billion, -7.21 billion, -23.88 billion, -22.83 billion, and -12.81 billion yuan respectively [4] - For the first three quarters of 2025, the company reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, but still recorded a net loss of 0.596 billion yuan, an improvement from the previous year's loss of 0.927 billion yuan [4]